Mylan Exits Biocon: Entire 5.64% Stake Sold for ₹3,679 Crore
In a significant move for the Indian biotechnology sector, Mylan Inc, a subsidiary of global healthcare giant Viatris, has completely exited its investment in Biocon Ltd. The massive stake sale was executed through block deals, marking a major shift in the company's shareholding pattern.
Details of the Mega Block Deal
Mylan Inc offloaded its entire holding of 9,19,67,019 equity shares, representing a 5.64% stake in Biocon. The transaction was split almost equally between the two major Indian exchanges: 4,59,83,510 shares were sold on the BSE, while 4,59,83,509 shares were transacted on the NSE.
The shares were sold at an average price of ₹400 per share, bringing the total transaction value to approximately ₹3,678.68 crore. This exit represents a total divestment by Mylan from the Indian pharma major through open market transactions.
Strong Institutional Appetite Drives Stock Rally
Despite the massive supply of shares hitting the market—which typically exerts downward pressure on stock prices—Biocon’s shares reacted positively. The stock witnessed a notable rally, climbing 6.52% to close at ₹437.30 on the BSE and 6.34% to settle at ₹437 on the NSE.
This price appreciation indicates robust institutional demand, as a diverse group of domestic and foreign investors stepped in to absorb the liquidity. The market's reaction suggests high confidence in Biocon's long-term growth prospects despite the change in its investor base.
Major Players Behind the Purchase
The block deal saw significant participation from India's leading financial institutions. On the NSE, a concentrated group of domestic mutual funds and insurance companies acquired the shares. Key buyers included:
- Mutual Funds: ICICI Prudential MF, Kotak Mahindra MF, HDFC MF, Aditya Birla Sun Life MF, and SBI MF.
- Insurance Companies: ICICI Prudential Life Insurance, Bajaj Life Insurance, and Axis Max Life Insurance.
The deal also attracted heavyweights from the global investment community. Foreign institutional investors (FIIs) such as Goldman Sachs Bank Europe SE, Citigroup Global Markets Singapore, BNP Paribas Arbitrage, and Norway’s Government Pension Fund Global were among the prominent buyers. Other participants included Ghisallo Capital Management and NRSGVCC.
Key Takeaways
- Complete Exit: Mylan Inc (part of Viatris) has liquidated its entire 5.64% stake in Biocon via block deals worth ₹3,679 crore.
- Market Resilience: Biocon shares rose by over 6% following the sale, signaling strong absorption capacity by institutional investors.
- Institutional Shift: The stake was transitioned from a single global healthcare entity to a diverse pool of domestic mutual funds, insurers, and major global funds like Goldman Sachs and Norway's Pension Fund.